MDT Stock Recent News

Medtronic (MDT) came out with quarterly earnings of $1.62 per share, beating the Zacks Consensus Estimate of $1.58 per share. This compares to earnings of $1.46 per share a year ago.

Building momentum in key franchises including Pulsed Field Ablation, TAVR, Cardiac Rhythm Management, Diabetes, Spine, and Neuromodulation GALWAY, Ireland , May 21, 2025 /PRNewswire/ -- Medtronic plc (NYSE: MDT), a global leader in healthcare technology, today announced financial results for its fourth quarter (Q4) and fiscal year 2025 (FY25), which ended April 25, 2025. Q4 Key Highlights Q4 revenue of $8.9 billion increased 3.9% as reported and 5.4% organic Q4 GAAP diluted EPS of $0.82 increased 67%; non-GAAP diluted EPS of $1.62 increased 11% Q4 operating margin increased 380 basis points; Q4 non-GAAP operating margin increased 90 basis points Q4 operating profit of $1.4 billion increased 36%; Q4 non-GAAP operating profit of $2.5 billion increased 8% Cardiac Ablation Solutions Q4 revenue increased nearly 30% on strength of pulsed field ablation (PFA) products; business delivered $1.0 billion in FY25 revenue Submitted Hugo™ RAS system to the U.S. Food and Drug Administration (FDA) f

Enables intense focus on highest margin growth drivers where Medtronic has leading core competencies Leading, scaled, direct-to-consumer Diabetes business poised to become standalone company; only company with a complete ecosystem to address intensive insulin management GALWAY, Ireland , May 21, 2025 /PRNewswire/ -- Medtronic plc (NYSE: MDT), a global leader in healthcare technology, today announced its intent to separate its Diabetes business into a new standalone company ("New Diabetes Company"). This strategic decision for both Medtronic and New Diabetes Company will create a more focused Medtronic, with a more simplified portfolio in high margin growth markets.

Medical device maker Medtronic plans to separate its diabetes business into a stand-alone company, the Wall Street Journal reported on Wednesday, citing people familiar with the matter.

Dividend stocks can be a smart way to generate steady income, especially in uncertain markets. However, not all dividend payers are created equal.

You can catch Opening Bid on Apple Podcasts, Spotify, YouTube, or wherever you get your podcasts. There has been one common theme from Corporate America throughout the last two months as the Trump administration's trade war has taken hold: shot-calling CEOs have been frozen in their normally hard-charging tracks.

Get a deeper insight into the potential performance of Medtronic (MDT) for the quarter ended April 2025 by going beyond Wall Street's top -and-bottom-line estimates and examining the estimates for some of its key metrics.

Investors stay optimistic about MDT due to its strength in the Cardiovascular portfolio.

Medtronic (MDT) closed the most recent trading day at $84.25, moving -1.01% from the previous trading session.

Medtronic has outperformed the S&P500 and other healthcare stocks from the S&P500 this year, but now faces a pivotal earnings event on the 21st of May. Cardiovascular portfolio strength, especially from Pulse Field Ablation products, and a convalescing medical surgical outlook, underpin our optimism, while gross margin and SG&A progress is likely to be seen. While the expected dividend hike may not be meaningful (potentially at less than 2%), that's not because MDT doesn't have the capabilities to be more generous with strong FCF coverage.